Business
Unaudited Interim Results to 30 June 2025
ProBiotix Health PLC reported unaudited interim results for the six months ending June 30, 2025, featuring a 33% increase in gross revenue to £1.34 million, up from £1.01 million in H1 2024. Gross profit also increased by 33% to £748,000, compared to £564,000 in the prior year. The company reduced its EBITDA loss, excluding share-based payments, by 52% to £112,000 from a £232,000 loss in H1 2024. Sales outside the USA grew significantly, increasing by 127% to £584,000 from £257,000. ProBiotix also reported a strong cash balance of £1.3 million, a notable increase from £865,000 in H1 2024. The net loss for the period reduced by 42% to £0.150 million (2024: £0.261 million). Disclaimer*
About this update from Probiotix Health Plc
[{"type":"text","content":"\n\n \n \n8 September 2025\n \nProBiotix Health plc\n(\"ProBiotix\" or the \"Company\" or, together with its subsidiary, the \"Group\")\n \nUnaudited Interim Results to 30 June 2025\n \nProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2025.\n \nKey Financial Highlights\n \n· Gross revenue +33% to £1.34m (H1 2024: £1.01m)\n· Gross profit +33% to £748,000 (H1 2024: £564,000)\n· EBITDA loss (excluding share-based payments) reduced by 52% to £112,000 (H1 2024: £232,000 loss)\n· Growth in all markets with sales outside USA +127% to £584,000 (H1 2024: £257,000)\n· Strong cash balance of £1.3m (H1 2024: £865,000)\n· Current trading robust with order book at a record level\n \nOperational Highlights\n \n· A number of new commercial partnerships secured across Europe, the US and Asia Pacific\n· Appointment of new sales executive in the US expected to drive further growth in North America\n· First commercial manufacturing of LPLDL completed through our CMO partnership in Canada\n· Launch of two new menopause-focused women's health concepts - YourBiotix MH and YourBiotix PMH\n· Initiated discussions with the Steno Research Foundation in Denmark, to explore a clinical study investigating the potential effects of LPLDL in individuals with diabetes\n \nSteen Andersen, CEO of ProBiotix, commented: \"We are pleased with the progress that has been achieved in the first half of 2025, which has resulted in another record performance. The increasing consumer awareness and market focus on preventive cardiometabolic supplement products continues to expand at an impressive pace (CAGR over the next 5-year period >8%), reflecting the growing demand for effective, science-backed health solutions.\n \n\"The successful product launches by our partners achieved over the past few years, and the accelerating consumer acceptance, confirms our belief in the tremendous long-term potential for the Company. We remain committed to executing the growth strategy to deliver sustainable va...